Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- Korosho Proposes 80% Price Rule for Single-enantiomer Drugs
October 19, 2011
- Korosho Presents Direction for PAL Amendment in 2012
October 19, 2011
- Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
- MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
- Health Minister Shows Positive Attitude Towards Participation in TPP Talks
October 17, 2011
- Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
- Korosho Task Force Discusses Upcoming Switch to Inactivated Polio Vaccine
October 17, 2011
- Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
- Revision of Ryotan-kisoku to Be Considered to Control Dispensing Point Services
October 13, 2011
- Chuikyo to Discuss “Dispensing Points” Offered by Pharmacies
October 12, 2011
- Drug Expenditure Higher than Apparent Due to Hidden Drug Expenditure: Korosho
October 12, 2011
- Headquarters for Promotion of Social Security Reform Holds 1st Meeting
October 11, 2011
- Korosho Expresses Opposition to Break-Up, Privatization of PMDA
October 11, 2011
- Decline in Research by Univ. Hospital Doctors Presents “Alarming Situation”: MEXT Official
October 10, 2011
- HPV Vaccines Competing for Public Subsidies; Are Parents Avoiding Vaccination by OB/GYN Doctors?
October 10, 2011
- Korosho Asks Committee to Discuss Re-pricing of Combination Drugs with Long-listed APIs
October 10, 2011
- Chuikyo to Focus on NHI Price Reduction for Long-listed Drugs: Dr Adachi
October 10, 2011
- PFSB’s Safety Division Calls For Revision of Tegretol Package Insert
October 10, 2011
- Korosho Announces Revision of Precautions in Prazaxa Package Insert
October 10, 2011
- MHLW to Set Up New System to Support Ultra-Orphan Drug Development
October 7, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…